Determinants of HIV Pre-Exposure Prophylaxis (PrEP) Retention among Transgender Women: A Sequential, Explanatory Mixed Methods Study.

Jack Andrzejewski, Heather A Pines, Sheldon Morris, Leah Burke, Robert Bolan, Jae Sevelius, David J Moore, Jill Blumenthal
Author Information
  1. Jack Andrzejewski: San Diego Joint Doctoral Program in Public Health, San Diego State University-University of California San Diego, San Diego, CA 92093, USA. ORCID
  2. Heather A Pines: School of Public Health, San Diego State University, San Diego, CA 92182, USA.
  3. Sheldon Morris: Department of Medicine, University of California San Diego, La Jolla, CA 92161, USA.
  4. Leah Burke: Department of Medicine, University of California San Diego, La Jolla, CA 92161, USA.
  5. Robert Bolan: LA LGBT Center, Los Angeles, CA 90038, USA.
  6. Jae Sevelius: Department of Psychiatry, Columbia University, New York, NY 10032, USA.
  7. David J Moore: Department of Psychiatry, University of California San Diego, La Jolla, CA 92093, USA.
  8. Jill Blumenthal: Department of Medicine, University of California San Diego, La Jolla, CA 92161, USA.

Abstract

Transgender women (TW) face inequities in HIV and unique barriers to PrEP, an effective biomedical intervention to prevent HIV acquisition. To improve PrEP retention among TW, we examined factors related to retention using a two-phase, sequential explanatory mixed methods approach. In Phase I, we used data from a trial of 170 TW who were provided oral PrEP to examine predictors of 24-week retention. In Phase II, we conducted 15 in-depth interviews with PrEP-experienced TW and used thematic analysis to explain Phase I findings. In Phase I, more participants who were not retained at 24 weeks reported sex work engagement (18% versus 7%) and substantial/severe drug use (18% versus 8%). In Phase II, participants reported drug use as a barrier to PrEP, often in the context of sex work, and we identified two subcategories of sex work. TW engaged in "non-survival sex work" had little difficulty staying on PrEP, while those engaged in "survival sex work" struggled to stay on PrEP. In Phase I, fewer participants not retained at 24 weeks reported gender-affirming hormone therapy (GAHT) use (56% versus 71%). In Phase II, participants prioritized medical gender affirmation services over PrEP but also described the bidirectional benefits of accessing GAHT and PrEP. TW who engaged in "survival sex work" experience barriers to PrEP retention (e.g., unstable housing, drug use) and may require additional support to stay in PrEP care.

Keywords

References

  1. AIDS Patient Care STDS. 2022 Jun;36(6):236-248 [PMID: 35687813]
  2. Sex Transm Infect. 2021 May;97(3):226-231 [PMID: 32366602]
  3. J Acquir Immune Defic Syndr. 2021 Sep 1;88(1):10-18 [PMID: 34397742]
  4. Transgend Health. 2018 Dec 26;3(1):210-219 [PMID: 30596148]
  5. Transgend Health. 2019 Aug 30;4(1):188-196 [PMID: 31482134]
  6. Ann Epidemiol. 2022 Jun;70:23-31 [PMID: 35398255]
  7. Addict Behav. 1982;7(4):363-71 [PMID: 7183189]
  8. Cult Health Sex. 2020 Sep 30;:1-13 [PMID: 32996407]
  9. AIDS Care. 2020 May;32(5):585-593 [PMID: 31482726]
  10. Behav Med. 2024 Jan-Mar;50(1):63-74 [PMID: 35993278]
  11. LGBT Health. 2021 Apr;8(3):181-189 [PMID: 33566718]
  12. Glob Public Health. 2016 Aug-Sep;11(7-8):1060-75 [PMID: 26963756]
  13. J Int AIDS Soc. 2016 Oct 18;19(7(Suppl 6)):21105 [PMID: 27760683]
  14. J Adolesc Health. 2017 May;60(5):549-555 [PMID: 28132744]
  15. Infection. 2016 Apr;44(2):151-8 [PMID: 26471511]
  16. J Acquir Immune Defic Syndr. 2016 Aug 15;72 Suppl 3:S235-42 [PMID: 27429189]
  17. Curr Opin HIV AIDS. 2019 Sep;14(5):393-400 [PMID: 31219887]
  18. AIDS Res Ther. 2023 Sep 20;20(1):69 [PMID: 37730616]
  19. AIDS Behav. 2023 May;27(5):1523-1530 [PMID: 36574185]
  20. AIDS Behav. 2022 Apr;26(4):1251-1259 [PMID: 34643827]
  21. J Acquir Immune Defic Syndr. 2022 Dec 15;91(5):453-459 [PMID: 36084200]
  22. Lancet HIV. 2015 Dec;2(12):e502-3 [PMID: 26614960]
  23. Expert Opin Drug Metab Toxicol. 2020 Jun;16(6):463-474 [PMID: 32250177]
  24. J Trauma Dissociation. 2014;15(2):169-83 [PMID: 24313294]
  25. AIDS Behav. 2016 Jul;20(7):1470-7 [PMID: 26336946]
  26. PLoS One. 2017 Nov 2;12(11):e0186457 [PMID: 29095843]
  27. AIDS Behav. 2023 Jul;27(7):2131-2162 [PMID: 36538138]
  28. J Int AIDS Soc. 2017 Apr 6;20(1):21422 [PMID: 28406598]
  29. Lancet. 2015 Jan 3;385(9962):4-7 [PMID: 25059948]
  30. J Acquir Immune Defic Syndr. 2008 May 1;48(1):97-103 [PMID: 18344875]
  31. AIDS Behav. 2009 Oct;13(5):902-13 [PMID: 19199022]
  32. Sex Roles. 2013 Jun 1;68(11-12):675-689 [PMID: 23729971]
  33. Soc Work Health Care. 2019 Feb;58(2):201-219 [PMID: 30321122]
  34. AIDS Behav. 2023 May;27(5):1600-1618 [PMID: 36520334]
  35. JMIR Form Res. 2023 Apr 13;7:e42418 [PMID: 37052977]
  36. J Subst Abuse Treat. 2021 Dec;131:108486 [PMID: 34217033]
  37. J Int AIDS Soc. 2019 Aug;22(8):e25385 [PMID: 31423756]
  38. Am J Public Health. 2019 Jan;109(1):e1-e8 [PMID: 30496000]

Grants

  1. K24 DA051328/NIDA NIH HHS
  2. P30 AI036214/NIAID NIH HHS

MeSH Term

Humans
Female
HIV Infections
Transgender Persons
Anti-HIV Agents
Pre-Exposure Prophylaxis
Transsexualism
Male

Chemicals

Anti-HIV Agents

Word Cloud

Created with Highcharts 10.0.0PrEPPhasesexTWuseHIVretentionparticipantsworkIIreportedversusdrugengagedwork"Transgenderwomenbarriersamongusedretained24weeks18%"survivalstayGAHTgenderaffirmationfaceinequitiesuniqueeffectivebiomedicalinterventionpreventacquisitionimproveexaminedfactorsrelatedusingtwo-phasesequentialexplanatorymixedmethodsapproachdatatrial170providedoralexaminepredictors24-weekconducted15in-depthinterviewsPrEP-experiencedthematicanalysisexplainfindingsengagement7%substantial/severe8%barrieroftencontextidentifiedtwosubcategories"non-survivallittledifficultystayingstruggledfewergender-affirminghormonetherapy56%71%prioritizedmedicalservicesalsodescribedbidirectionalbenefitsaccessingexperienceegunstablehousingmayrequireadditionalsupportcareDeterminantsPre-ExposureProphylaxisRetentionWomen:SequentialExplanatoryMixedMethodsStudysubstancetransgender

Similar Articles

Cited By (1)